mixed infiltrate with a mainly perivascular and pericellular distribution in the superficial and deep dermis and the hypodermis have been notified.\(^2\)\(^3\)\(^4\)

However, our histological findings are reminiscent of the pauci-inflammatory thrombogenic vasculopathy that occurs seriously ill hospitalized COVID-19 patients with COVID-19. This thrombogenic vasculopathy is due to activation of the complement pathways and an associated procoagulant state.\(^5\)\(^6\) However, no cases of thrombotic vasculopathy have been reported to date in asymptomatic children or young adults with acral lesions.

In conclusion, the histological findings of purpura-erythema multiforme appearing on soles and heels reveal thrombogenic vasculopathy similar to that found in COVID-19 patients with severe forms of the disease, which suggests that these acral lesions may be related to SARS-COV-2 or its etiopathogenesis.

**Acknowledgement**

The patients in this manuscript have given written informed consent to publication of their case details. We gratefully acknowledge the multidisciplinary team that contributed to the patient’s medical care, especially Dr. Carmen Boldova Aguar.

**Conflicts of interest**

The authors declare that they have no conflict of interest.

**Funding sources**

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

M.F. García-Gil,\(^1\)\(^*\) M. García García,\(^2\) J. Monte Serrano,\(^1\) L. Prieto-Torres,\(^1\) M. Ara-Martin\(^1\)

\(^1\)Department of Dermatology and Venereology, Lozano Blesa University Clinical Hospital, Zaragoza, Spain

\(^2\)Department of Pathology, Lozano Blesa University Clinical Hospital, Zaragoza, Spain

\(^*\)Correspondence: M.F. García-Gil. E-mail: miguelgarcigil@outlook.com

**References**

1. Fernandez-Nieto D, Jimenez-Cauhe J, Suarez-Valle A et al. Characterization of acute acro-ischemic lesions in non-hospitalized patients: a case series of 132 patients during the COVID-19 outbreak. *J Am Acad Dermatol* 2020; S0190-9622(20)30709-X. https://doi.org/10.1016/j.jaad.2020.04.093

2. Romaní J, Baselga E, Mitjà O et al. Chilblain and acral purpuric lesions in Spain during COVID confinement: retrospective analysis of 12 cases. *Acta Dermosifiliogr* 2020; S0001-7310(20)30087-9. https://doi.org/10.1016/j.ad.2020.04.002

3. Kolivras A, Dehavy F, Delplace D et al. Coronavirus (COVID-19) infection-induced chilblains: a case report with histopathological findings. *JAAD Case Rep* 2020. https://doi.org/10.1016/j.jdcr.2020.04.011

4. Recalcati S, Barbagallo T, Frassin LA et al. Acral cutaneous lesions in the time of COVID-19. *J Eur Acad Dermatol Venereol* 2020. https://doi.org/10.1111/jdv.16533

5. Magro C, Mulvey JJ, Berlin D et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. *Transl Res* 2020; S1931-5244(20)30070-0. https://doi.org/10.1016/j.trsl.2020.04.007

6. Zhang Y, Cao W, Xiao M et al. Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acro-ischemia. *Zhonghua Xue Ye Xue Za Zhi* 2020; 41: E006.

DOI: 10.1111/jdv.16644

---

**Are chilblain-like acral skin lesions really indicative of COVID-19? A prospective study and literature review**

To the Editor

Recently, young COVID-19 patients have presented with erythematous and purpuric acral lesions similar to chilblains.\(^1\)\(^3\) Despite the scarcity of published cases, this topic has attracted significant mass media attention.\(^3\) Dermatologists have noted that more people than would be expected at this time of year are seeking medical attention for these chilblain-like lesions. Some have suggested that people presenting with this manifestation should be tested and isolated.\(^2\) Determining the accuracy of this association is, therefore, crucial.

To establish the real prevalence of COVID-19 in patients with acral skin lesions, we firstly evaluated all the cases of acral lesions presented in dermatology and paediatrics departments and family doctors’ offices in an eastern Spanish region over a 3-week period. Then we prospectively performed a SARS-CoV-2 PCR on nasopharyngeal aspirates taken from all available patients to determine whether their cutaneous manifestations were predictive of a positive result.

To put our findings into context, we reviewed all the articles published before May 2020 concerning COVID-19 patients with cutaneous lesions.

We evaluated 58 patients, whose characteristics are summarized in Table 1. In most cases, lesions were chilblain-like. Fifteen patients had already been tested, and only one had a positive result: an 85-year-old man admitted for severe Covid-19 pneumonia. He had an ulcer on a toe that was finally determined to be vascular in nature.

We performed prospective PCR testing in 24 patients. All test results were negative. In total, then, PCR was negative in 38 patients and positive in a single patient whose lesion was very unlikely to be due to COVID-19.

Our bibliography search returned 97 articles and we found two more through cross-references. Nine of these articles dealt with acral lesions specifically. Their results are summarized in Table 2.
Table 1 Epidemiological characteristics and clinical features of 58 patients with acral lesions

| Characteristic                                    | Value†                  |
|--------------------------------------------------|-------------------------|
| **Age**                                          |                         |
| Median (range)                                    | 14.0 years (3 months–85 years) |
| Sex                                              |                         |
| Male                                             | 29 (50)                 |
| Female                                           | 29 (50)                 |
| History of thrombosis (N = 53)                   |                         |
| Yes                                              | 2 (3.8)                 |
| No                                               | 51 (96.2)               |
| History of dermatologic conditions (N = 54)      |                         |
| Yes                                              | 7 (13.0)                |
| No                                               | 47 (87.0)               |
| Dermatologic history                             |                         |
| Atopic dermatitis                                | 3 (5.5)                 |
| Allergic contact dermatitis                      | 1 (1.8)                 |
| Psoriasis                                        | 1 (1.8)                 |
| Recurrent herpes zoster                          | 1 (1.8)                 |
| Pemiosis                                         | 1 (1.8)                 |
| COVID-19 related symptoms (N = 52)               |                         |
| Yes                                              | 11 (21.2)               |
| No                                               | 41 (78.8)               |
| Exposure or contact (N = 55)                     |                         |
| Contact with a confirmed case                    | 12 (21.8)               |
| Contact with a suspected case                    | 7 (12.1)                |
| No suspicious contacts                           | 36 (65.5)               |
| Location of lesions                              |                         |
| Hands                                            | 9 (15.5)                |
| Feet                                             | 36 (62.1)               |
| Hands and feet                                   | 13 (22.4)               |
| Symptoms (N = 53)                                |                         |
| Pain                                             | 17 (32.1)               |
| Pruritus                                         | 20 (37.7)               |
| Pain and pruritus                                | 5 (8.6)                 |
| Asymptomatic                                     | 11 (20.8)               |
| Morphological features of the lesions            |                         |
| Chilblain-like                                    | 42 (72.4)               |
| Pupuric                                           | 3 (5.2)                 |
| Maculo-papular                                    | 3 (5.2)                 |
| Vesiculobullous                                   | 3 (5.2)                 |
| Eczematous                                        | 3 (5.3)                 |
| Paronychia                                        | 2 (3.4)                 |
| Ulcer                                            | 1 (1.7)                 |
| Desquamation                                     | 1 (1.7)                 |
| Time from development of lesions to PCR test     |                         |
| Median (range)                                    | 12 days (1–28 days)     |
| Time from COVID-19 symptoms to development of lesions (N = 11) |     |
| Median (range)                                    | 7 days (0–42 days)      |
| PCR result                                        |                         |
| Positive                                          | 1 (1.7)                 |
| Negative                                          | 38 (65.5)               |
| Not performed                                     | 19 (32.8)               |

†Unless otherwise indicated, all values are expressed in number (%) of patients.

Data published in the literature are heterogeneous, as are the methods employed to collect them. The first papers looked at cutaneous manifestations in patients with confirmed SARS-CoV-2 infection. This approach cannot reveal whether this dermatologic manifestation is a specific marker of SARS-CoV-2 infection, since patients without COVID-19 are not included. The other approach, which we have followed, is to analyse all patients with acral lesions. This can be done retrospectively, reporting on patients in the sample who have already been tested, or prospectively, performing the test on all available patients, regardless of whether they have symptoms. The retrospective method has a significant risk of confounding bias: due to the scarcity of COVID-19 tests, they are usually reserved for patients with COVID-19-related symptoms, who are obviously more likely to test positive.

All previous studies including only patients with cutaneous acral lesions (summarized in Table 2) have been retrospective, and only a minority of patients were tested. In total, 12 out of at least 49 tested patients were positive (24.5%). Combined with our results, they total 13 positives out of 88 tests (14.8%).

There are two possible explanations for the high proportion of negative results: (i) A high number of false negatives. (ii) The lesions are not related to SARS-CoV-2 infection. The low prevalence of an infected contact in our sample, after 3 weeks of strict confinement in Spain, makes the possibility of being infected in our cohort less likely. The diffusion of this entity by the mass media may have caused patients who would not normally consult to do so. Other possible explanations include a concomitant parvovirus B19 outbreak or trauma-induced lesions.

Our study suggests that acral skin lesions are not a specific marker of SARS-CoV-2 infection. Although larger prospective studies are needed, current evidence indicates that acral skin lesions should not be regarded as a sign of COVID-19 in otherwise asymptomatic patients.

A. Docampo-Simón,1,2 M.J. Sánchez-Pujol,1 G. Juan-Carpena,1,2 J.C. Palazón-Cabanes,1 E. Vergara-De Caso,1 L. Berbegal,2 I. Poveda-Montoyo,2 N. Pastor-Tomás,3 J. Mataix-Díaz,4 C. Terencio-Alemany,5 A. Martínez-Torres,9 J. Miralles-Botella,7 M. Blanes-Martínez,1 I. González-Villanueva,1 I. Betiloch-Mas1

1Department of Dermatology, Alicante University General Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain, 2Department of Dermatology, Hospital Marina Salud Denia, Denia, Spain, 3Department of Dermatology, Elda University General Hospital, Elda, Spain, 4Department of Dermatology, Hospital Marina Baixa, Villajoyosa, Spain, 5Department of Dermatology, Vistahermosa Clinic, Alicante, Spain, 6Department of Dermatology, Vinalopó University Hospital, Elche, Spain, 7Department of Dermatology, San Juan University Hospital, San Juan de Alicante, Spain

*Correspondence: A. Docampo-Simón. E-mail: docamposimon@gmail.com
Table 2  Studies on patients with acral skin lesions

| Study | No. of patients | Prospective/retrospective | PCR (positive/total) | Serological test (positive/total) | Biopsy |
|-------|-----------------|---------------------------|----------------------|-----------------------------------|--------|
| Mazzotta and Troccoli T. Acute acro-ischaemia in the child at the time of COVID-19. *Eur J Pediatr Dermatology* 2020 | 1 ("few dozen" more through Whatsapp!) | Retrospective | 2/unknown | 0/0 | No |
| Kolivras A, Dehavay F, Delplace D, et al. Coronavirus (COVID-19) infection-induced chilblains: a case report with histopathological findings. *JAAD Case Reports* 2020 | 1 | Retrospective | 1/1 | 0/0 | Yes |
| Aalamth A, Aldaraji W. A case of COVID-19 presenting in clinical picture resembling chilblains disease. First report from the Middle East. *Clin Exp Dermatol* 2020 | 2 | Retrospective | 2/2 | 0/0 | No |
| Estebanez A, Perez-Santiago L, Silva E, Guillen-Climent S, Garcia-Vazquez A, Ramon MD. Cutaneous manifestations in COVID-19: a new contribution. *J Eur Acad Dermatology Venereol* 2020 | 1 | Retrospective | 1/1† | 1/1† | No |
| Romani J, Baselga E, Mitja O, et al. Lesiones perniciosas y acrales en España durante el confinamiento por COVID: análisis retrospectivo de 12 casos. *Actas Dermosifiliogr* 2020 | 12 | Retrospective | 0/12 | 0/5 (rapid tests) | Yes |
| Piccolo V, Neri I, Filippeschi C, et al. Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients. *J Eur Acad Dermatology Venereol* 2020; jdv.16526 | 63 | Retrospective | 2/11 | 2/6 | No |
| Landa N, Mendieta-Eckert M, Fonda-Pascual P, Aguirre T. Chilblain-like lesions on feet and hands during the COVID-19 Pandemic. *Int J Dermatol* 2020. ijd.14937 | 6 | Retrospective | 3/4 | 0/1 | No |
| Recalcati S, Barbagallo T, Frasin LA, et al. Acral cutaneous lesions in the Time of COVID-19. *J Eur Acad Dermatol Venereol* 2020 | 14 | Not specified | 0/5 | 0/0 | Yes |
| Fernandez-Nieto D, Jimenez-Cauhe J, Suarez-Valle A, et al. Characterization of acute acro-ischaemic lesions in non-hospitalized patients: a case series of 132 patients during the COVID-19 outbreak. *J Am Acad Dermatol* 2020 | 132 | Retrospective | 2/11 | 0/0 | No |
| Docampo et al. | 58 | Retrospective and prospective | Retrospective: 1/15 | Retrospective 0/1 | No |

†The authors do not specify whether PCR or serology were performed.

References
1 Aalamth A, Aldaraji W. A case of COVID-19 presenting in clinical picture resembling chilblains disease. First report from the Middle East. *Clin Exp Dermatol* 2020. https://doi.org/10.1111/ced.14243 [Epub ahead of print].
2 Kolivras A, Dehavay F, Delplace D et al. Coronavirus (COVID-19) infection-induced chilblains: a case report with histopathological findings. *JAAD Case Reports* 2020. https://doi.org/10.1016/j.jdercr.2020.04.011 [Epub ahead of print].
3 Mazzotta F, Troccili T. Acute acro-ischaemia in the child at the time of COVID-19. *Eur J Pediatr Dermatol [Internet]* 2020. URL https://www.ejped.com/images/acroschisma-ENG.pdf (last accessed: 30 April 2020).
4 Coronavirus: Doctors learn more about new COVID-19 symptom, COVID toes. URL https://eu.usatoday.com/story/news/health/2020/04/27/coronavirus-doctors-learn-more-new-covid-19-symptom-covid-toes/3031743001/ (last accessed: 29 April 2020).
5 Recalcati S. Cutaneous manifestations in COVID-19: a first perspective * by Recalcati S. *J Eur Acad Dermatol Venereol* 2020. https://doi.org/10.1111/jdv.16519 [Epub ahead of print].
6 Bouaziz J, Duong T, Jachiet M et al. Vascular skin symptoms in COVID-19: a french observational study. *J Eur Acad Dermatology Venereol* 2020. https://doi.org/10.1111/jdv.16544 [Epub ahead of print].
7 Galván Casas C, Catalá A, Carretero Hernández G et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. *Br J Dermatol* 2020. https://doi.org/10.1111/bjd.19163 [Epub ahead of print].
8 Gallagher KM, Updegraff JA. Health message framing effects on attitudes, intentions, and behavior: a meta-analytic review. *Ann Behav Med* 2012; 43: 101–116.
9 Piccolo V, Neri I, Filippeschi C et al. Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients. *J Eur Acad Dermatology Venereol* 2020. https://doi.org/10.1111/jdv.16526 [Epub ahead of print].

DOI: 10.1111/jdv.16665